anakinra
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.
- Target
- Interleukin-1 receptor type 1
- Mechanism
- Interleukin-1 receptor antagonist
pharma · Haemophilia A · Still's Disease, Juvenile Onset
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Stockholm, JP HQ
2020 Founded
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, JP
- Founded
- 2020
- Employees
- 6
- Programs
- 7
- Drugs
- 12
- Patents
- 0
Swedish Orphan Biovitrum pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Swedish Orphan Biovitrum drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
efanesoctocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Swedish Orphan Biovitrum's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
octocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Swedish Orphan Biovitrum's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
US regulatory status: approved. Molecular target: Activin receptor type-1.
- Target
- Activin receptor type-1
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
pegcetacoplan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C3.
- Target
- Complement C3
- Mechanism
- Complement C3 inhibitor
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.
-
Development asset linked to Swedish Orphan Biovitrum in public FDA and regional records.